SEC Form 4 · accession 0001171843-18-002049
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sherrington Robin
Officer — EVP Bus. & Corp. Development
Period of report
Mar 15, 2018
Accepted (ET)
Mar 16, 2018 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Mar 15, 2018 | M | 3,086 | $3.77 | A | 7,820 | D | |
| Common SharesF2 | Mar 15, 2018 | F | 1,928 | $4.625 | D | 5,892 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F3 | $3.77 | Mar 15, 2018 | M | 3,086 | D | — | Mar 16, 2018 | Common Shares | 3,086 | 0 | D |
Explanation of responses
- F1The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
- F2Represents the closing price of the Company's common shares on March 14, 2018, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
- F3The shares subject to the option fully vested on December 31, 2011. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.